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Abstract
Normal tissue toxicity markedly reduces the therapeutic index of genotoxic anti-cancer agents 
including ionizing radiation. Countermeasures against tissue damage caused by radiation are 
limited by their potential to also protect malignant cells and tissues. Here we tested a panel of 
signal transduction modifiers for selective radioprotection of normal but not tumor tissues. These 
included three inhibitors of GSK3 (LiCl, SB216763 and SB415286) and two inhibitors of NF-κB 
(ethyl pyruvate and RTA 408). Among these, the thiol reactive triterpenoid RTA 408 emerged as a 
robust and effective protector of multiple organ systems (gastrointestinal, skin and hemopoietic) 
against lethal doses of radiation. RTA 408 preserved survival and proliferation of crypt cells in 
lethally irradiated small intestines while reducing apoptosis incidence in crypts and villi. In 
contrast, RTA 408 uniformly inhibited growth of established CWR-22Rv1, LNCaP/C4-2B, PC3 
and DU145 xenografts either alone or combined with radiation. Anti-tumor effects in vivo were 
associated with reduced proliferation and intratumoral apoptosis and with inhibition of NF-κB-
dependent transcription in PC3 cells. Selective protection of normal tissue compartments by RTA 
408 critically depended on tissue context and could not be replicated in vitro. Collectively, these 
data highlight the potential of RTA 408 as a cytoprotective agent that may be safely used in 
chemoradiation approaches.
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Introduction
Radiation therapy is the most common therapeutic modality across a wide range of 
malignant diseases including prostate cancer. However, the delivery of curative radiation 
doses is hampered by acute or chronic ‘collateral damage’ affecting normal tissues. When 
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treating tumors in the abdominal cavity, toxicity to the intestine and the bladder are often 
dose-limiting (1). Highly targeted methods to deliver radiation specifically to disease sites 
alleviate radiation toxicity, yet 40% – 50% of patients with locally advanced prostate 
cancers recur locally following treatment (2). Hence protection of normal tissue will be a 
critical element of future dose escalation trials in patients with locally advanced prostate 
cancer. Existing radiation protectors including amifostine (3) are of limited utility in 
protecting the small and large intestines against radiation effects.
Inflammation is a key element of the radiation response of normal and tumor tissues and is 
commonly associated with increased activity of nuclear factor-kappaB (NF-κB) (4, 5). 
Previously we demonstrated that several inhibitors of canonical NF-κB activation improved 
survival of lethally irradiated zebrafish embryos and preserved gastrointestinal morphology 
and function (6). Inhibitors of glycogen synthase kinase (GSK)3 similarly protect normal 
tissues including the gastrointestinal tract (7, 8). While the role of GSK3β in cell stress 
responses is complex (for review (9)), it has been implicated in modifying NF-κB-dependent 
transcription of genes encoding proinflammatory proteins (10, 11).
Here we performed a side-by-side comparison of radioprotective properties of five 
compounds targeting either GSK3 and/or NF-κB with a focus on the gastrointestinal tract. 
We report that the triterpenoid RTA 408 provides robust radiation protection to the GI 
system of mice and markedly improves overall survival of lethally irradiated mice. 
Importantly, normal tissue protection by RTA 408 is contrasted by inhibition of human 
prostate cancer xenograft growth in mice.
Materials and Methods
Materials and cells
Compounds were obtained from the following sources: Ethyl pyruvate and lithium chloride 
(Sigma-Aldrich), SB216763 and SB416583 (Tocris Bioscience), amifostine (Medimmune), 
and 2-cyano-3,12- dioxooleana-1,9(11)-dien-28-oic acid (CDDO) derivative RTA 408 
(REATA Pharmaceuticals). Prostate cancer cells (PC3, LNCaP/C4-2B, DU145 and 
CWR-22Rv1) were originally obtained from ATCC or Dr. Thomas Pretlow (Case Western 
Reserve University) and generously provided by Dr. Marja Nevalainen (Thomas Jefferson 
University) and immortalized NHPrE-1 and BHPrE-1 prostate epithelial cells were a gift 
from Dr. Simon Hayward (Vanderbilt University Medical Center). Normal primary prostate 
epithelial cells (PrEC) were from Lonza (Allendale, NJ). The prostate cancer cell lines were 
authenticated on a regular basis by monitoring cell morphology, androgen-responsiveness 
and the expression of cell lines specific markers. Normal primary epidermal keratinocyte 
cultures were established using standard protocols. Cells were routinely tested for 
mycoplasma contamination using MycoSensor PCR assay kit (Stratagene). Tumor cells 
were grown in RPMI1640 supplemented with 10% FBS (Corning Cellgro). Normal and 
immortalized prostate epithelial cells and primary keratinocytes were grown in specialty 
media (Lonza). For in vivo imaging, PC3 prostate carcinoma cells were stably transfected 
with reporter plasmids (pGL4.51[luc2/CMV/Neo] and pNL3.2.NF-κB-RE[NlucP/NF-κB-
RE/Hygro], Promega) encoding firefly luciferase (FLuc) and NanoLuc® luciferase, 
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respectively and luciferase reporter activity tested using reporter-specific in vitro assays 
(Promega).
Toxicity studies in mice
C57Bl/6 mice (6–8 weeks old) were from Charles River Laboratories. Mice were kept in 
pathogen-free conditions and handled in accordance with the requirements of the Guideline 
for Animal Experiments and after approval of the experimental protocols by the Institutional 
Animal Care and Use Committee of Thomas Jefferson University. Ionizing radiation (IR) 
was administered at doses ranging from 5 to 30 Gy using a 250-kVp X-ray machine 
(PanTak, East Haven, CT) with 50-cm source-to-skin distance and a 2-mm copper filter. The 
dose rate was approximately 1.4 Gy/min. Drugs were uniformly administered by i.p. 
injection for up to 2 days prior to IR treatment, and on days 1, 2, and 3 post-IR treatment as 
indicated. For comparison of RTA 408 and amifostine, mice received one dose (17.5 mg/kg) 
of RTA 408 24 h prior IR (whole body, 9 Gy), one dose 1 hr prior to IR, and 2 additional 
doses 24 and 48 h after IR; amifostine was injected once (250 mg/kg) 15 min prior to IR. All 
injections were done i.p. Animals were euthanized at the end of the observation period, or 
when weight loss reached or exceeded 20% of the initial weight, or if they showed signs of 
severe morbidity (lethargy, hunched posture and/or shivering or severe diarrhea). Kaplan-
Meier survival curves were compared by using the Log-rank (Mantel-Cox) test.
Growth inhibition of prostate cancer xenografts
Prostate carcinoma cells were inoculated by subcutaneous injection (5×106 per mouse) into 
the lower abdominal skin of male Foxn1nu (nude) mice (6–8 weeks old; Charles River 
Laboratories). Tumor progression was monitored by caliper measurements and by in vivo 
live imaging (see below). Xenografts were allowed to grow for 2–3 weeks prior to 
treatment. RTA 408 (17.5 mg/kg) or vehicle control (DMSO) were administered 
intrperitoneally three times per week until the end of the observation periods. To assess 
effects of the combination of RTA 408 and IR, radiation (5 Gy) was administered at 
different time points as indicated. Tumor volumes were calculated by multiplying the two 
longest planar axes measured by the depth of the tumor (as determined by caliper 
measurements). Mixed effects regression models were used to determine statistical 
significance of tumor growth data over time.
In situ imaging of xenografts and image analysis
For firefly luciferase-based in vivo live imaging, mice were injected i.p. with 200 µl D-
luciferin in PBS (15 mg/ml) per 20 g of mouse body weight 15 minutes prior to imaging, 
and imaged using an IVIS In Vivo Imaging System (Caliper Life Sciences). For in vivo 
imaging of the NanoLuc® luciferase under the control of the NF-κB response element, 100 
µl of the NanoGlo® substrate (10 µg) (Promega, Madison, WI) were injected via tail vein. 
Image analysis and quantitation was done using Living image 4.2 software (Caliper 
LifeSciences). Luciferase-positive areas on individual images were selected as Regions of 
Interest (ROI) with a 14% threshold. Planar spectral images were automatically analyzed by 
the software. Total counts for all pixels inside the ROI were recorded. At least 3 animals 
from each experimental group were used for each time point.
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Histology, immunohistochemistry and in situ apoptosis detection
For histological, immunofluorescent and direct fluorescent analyses, tissue samples (eg. 
small intestines, tumors) were embedded in the OCT compound (Tissue-Tek), and cryo-
sectioned (7 µm). Hematoxylin and Eosin staining was done on ethanol/acetic acid fixed 
slides. Apoptosis incidence was determined by terminal deoxynucleotidyl transferase dUTP 
nick end labeling (TUNEL) using the In Situ Cell Death Detection Kit (Roche Applied 
Science) and 4',6-diamidino-2-phenylindole (DAPI) counterstain. Quantitative analysis was 
done using ImagePro software (Media Cybernetics, Rockville, MD) on at least 6 different 
and independent microscopic fields for each treatment condition. Indirect 
immunofluorescence was performed by incubation with primary antibodies for cleaved 
PARP (Asp214) Human Specific (Cell Signaling), M30CytoDEATH (Roche Applied 
Science), or Ki-67 (abcam) for 1 h at room temperature or overnight at 4°C followed by 
secondary antibodies labeled with either Alexafluor488 or Alexafluor594 (BD Biosciences). 
Sections were counterstained with DAPI and slides were mounted using anti-fade Fluorosafe 
reagent (Calbiochem).
In vitro cell growth and viability assays
Cells were seeded in 96-well plates at 15,000 cells/well; after 24 h, RTA 408 or vehicle 
were added in triplicate. After 72 h, attached cells were fixed with 70% ethanol, stained with 
crystal violet solution (0.2% crystal violet in 2% ethanol), and quantitated by measuring 
absorbance (ODA595). Metabolic activity was determined after 72 h by addition of WST-1 
reagent (Roche; 10 µL per 100 µL supernatant) for at least 3 hr at 37° C, followed by 
measuring absorbance at ODA450 with a reference of ODA650 and using wells containing 
media without cells for background subtraction. Statistical differences betweeen treatment 
groups were determined using one-way ANOVA with Tukey’s post-test correction 
(GraphPad Prism).
Immunoblot analyses
Prostate carcinoma cell lines were treated for 24 h with RTA 408 or vehicle at the 
concentrations indicated. Immunoblots were reacted with (a) PARP-1 primary antibody 
(C2-10) (Santa Cruz Biotechnology, Dallas, TX) and IRDye 800CW goat anti-mouse IgG1-
specific secondary antibody; (b) Cleaved Caspase-3 (Asp175) (5A1E) primary antibody 
(Cell Signaling) and IRDye 800CW Donkey anti-Rabbit IgG (H + L) secondary antibody; 
(c) Cleaved Caspase-8 (Asp384) (11G10) primary antibody (Cell Signaling) and IRDye 
800CW goat anti-mouse IgG1-specific secondary antibody, or (d) M30CytoDEATH 
primary antibody (Roche Applied Science) and IRDye 800CW Goat Anti-Mouse IgG2b 
specific secondary antibody; all secondary antibodies were from LICOR. Filters were 
analyzed on a LICOR Odyssey imaging system.
Colony formation assays
Cells were seeded at clonogenic densities in T-25 flasks and treated with RTA 408 at 
various concentrations or DMSO, at 24 and 1 h prior to radiation exposure. IR was 
administered at 0, 2, 4, 6, and 8 Gy. All treatments were performed in biological triplicate. 
Following IR, flasks were incubated for 2 weeks. Colonies were identified by crystal violet 
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staining; those containing ≥50 cells were counted. The data were fit to a linear quadratic 
model for cell survival by using GraphPad Prism software and the equation Y=exp(−a*x
−b*x^2) (12). Statistically significant differences between drug and control curves were 
determined by using two-way ANOVA.
Results and Discussion
Inhibitors of canonical NF-κB activation and of GSK3 improve survival of lethally irradiated 
mice
We performed a side-by-side comparison of several NF-κB and GSK3 inhibitors on mice 
challenged with a lethal whole body radiation dose (8 Gy) (Figure 1). All of the compounds 
reportedly protect against or mitigate radiation injury in different experimental settings 
either in vitro or in vivo. They included two inhibitors of canonical NF-κB signaling (ethyl 
pyruvate (13)) and RTA 408 (14))(Figure 1a), and three GSK3 inhibitors including lithium 
chloride (LiCl) (8), SB415286 (8), and SB216763 (8) (Figure 1b,c). Ethyl pyruvate 
interferes with NF-κBp65 signaling by covalently modifying a reactive cysteine residue 
(Cys36) of the NF-κBp65 subunit (15). RTA 408 is a variant of the triterpenoid CDDO that 
reversibly and covalently modifies reactive cysteine residues on multiple proteins including 
several of potential relevance to radiation protection. Specifically, binding of CDDO to 
Cys179 in IKKβ leads to inhibition of canonical NF-κB signaling (16) and binding to 
KEAP1 leads to increased levels of the transcription factor Nrf2 and of multiple antioxidant 
and phase-2 defense enzymes (17). RTA 408 was included in the screen because we 
previously observed robust radioprotection of zebrafish embryos by another variant of 
CDDO (CDDO-TFEA) (6). SB415286 and SB216763 are ATP competitive GSK3 inhibitors 
(18) whereas LiCl increases inhibitory phosphorylation of GSK3 (19). To allow direct side-
by-side comparison all drugs were given using a standardized regimen, i.e. for 1 day and 1 h 
prior to radiation and daily for three days after. Drug dosages were guided by published 
results and administration was by intraperitoneal injection. We observed various levels of 
radiation protection with each of the compounds tested. The CDDO derivative RTA 408 
provided robust and consistent levels of radiation protection (100% at 30 days post IR (8 
Gy)) either as a single compound (Figure 1a) or in combination with the GSK3 inhibitor 
SB216763 (Figure 1c). In agreement with an earlier report (13), ethyl pyruvate also 
markedly increased survival of lethally irradiated mice (Figure 1a). Interestingly, the 
survival advantage provided by RTA 408 was compromised when combined with SB415286 
but not when combined with SB216763 (Figure 1c). Similarly, survival of lethally irradiated 
mice treated with a combination of RTA 408 and LiCl was slightly lower than survival of 
mice receiving RTA 408 alone (Figure 1c). Finally, RTA 408 produced levels of radiation 
protection similar to amifostine, the only currently approved radiation protector (Fig. 1d). 
These results encouraged us to further investigate tissue protection provided by RTA 408 
alone.
RTA 408 protects mice against gastrointestinal syndrome and death after lethal doses of 
radiation
Next, we investigated the effect of RTA 408 on the small intestine in C57Bl/6 mice 
irradiated at a dose (9 Gy) that causes death from gastrointestinal syndrome within 10–15 
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days (20). We observed that RTA 408 preserved the integrity of the mucosal lining of the 
small intestine of lethally irradiated mice (Figure 2a). Mice that did not succumb to 
gastrointestinal syndrome lived beyond 30 days after IR, consistent with radiation protection 
of multiple organs including the hemopoietic system. Furthermore, as determined by Ki-67 
staining RTA 408-treated mice revealed robust proliferation in the crypt area at 2 and 7 days 
after IR whereas radiation alone (9 Gy) markedly reduced proliferation in this tissue 
compartment concurrent with extensive tissue destruction (Figure 2a). RTA 408 also 
significantly reduced radiation-induced apoptosis in both, villi and crypts as determined by 
TUNEL staining (Figure 2b). This effect extended to the skin, in which RTA 408 similarly 
reduced the apoptosis incidence caused by radiation exposure (Supplementary Figure S1).
RTA 408 inhibits cell growth and survival of human prostate cancer in vivo
To address whether the cytoprotective effects of RTA 408 extended to tumor cells, we first 
tested the effects of RTA 408 on four different prostate cancer cell lines representing 
advanced, androgen-independent tumor stages (LNCaP/C4-2B, CWR22Rv1, DU145 and 
PC3). We observed robust tumor growth inhibition by RTA 408 of established xenografts 
(tumor size > 30 mm3 when treatment commenced) of all four cell lines tested even in the 
absence of radiation. Tumor growth, as determined by caliper measurements, is shown in 
Figure 3a and representative in vivo tumor images at different days post-treatment in 
Supplementary Figure S2. In marked contrast to the protective effects observed in normal 
tissues, RTA 408 did not radioprotect PC3 xenotransplants. Rather, when used in 
combination with radiation, RTA 408 amplified the anti-tumor effect of radiation alone 
(p=0.001) (Figure 3b). In vivo imaging revealed complete tumor growth inhibition in 
animals that received both radiation and RTA 408 at 17.5 mg/kg (see insert, Figure 3b) but 
not in mice treated with 5 mg/kg RTA 408 (not shown). RTA 408 induced high levels of 
intratumoral apoptosis as determined by detection of fragmented DNA (TUNEL), cleaved 
PARP, and the caspase3 cleavage product of cytokeratin18 (Figure 4a). The antibodies used 
to detect cleaved PARP and cytokeratin18 do not crossreact with mouse tissues indicating 
that RTA 408 induced apoptosis of human tumor cells in situ. RTA 408-dependent 
inhibition of PC3 xenografts was associated with significantly reduced proliferation as 
determined by Ki-67 staining (Figure 4b).
RTA 408 decreases growth and survival of human prostate cancer cells in vitro
Next, we examined dose-dependent effects of RTA 408 on prostate cancer cells in vitro. 
Within 24 h of exposure, RTA 408 (1 µM) induced varying degrees of apoptosis in all four 
prostate cancer cell lines as determined by detection of cleaved caspase3, cytokeratin18, and 
PARP-1 in both attached and, more prominently, in cells detached from substrate 
(Supplementary Figure S3). By contrast, caspase 8 cleavage was only marginally detected in 
DU145 at the higher doses of RTA 408 (0.5–1 µM) tested but not the other three cell lines. 
As determined by clonogenic survival assays, RTA 408 radiosensitized all four prostate 
cancer cell lines under investigation with the strongest effects observed in DU145 and 
LNCaP/C4-2B cells (Supplementary Figure S4). As assessed by crystal violet staining and 
by WST assay, RTA 408 reduced viability of all four prostate cancer cell lines in a dose-
dependent fashion (Figure 5a). The IC50 for inhibition of in vitro growth and survival of 
these cell lines ranged from 250 to 750 nM. Interestingly, RTA 408 also inhibited in vitro 
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growth and survival of normal primary prostate epithelial cells (PrEC), the immortalized 
NHPr-E1 and BHPrE-1 prostate cells and, primary human epidermal keratinocytes 
(NHEK-1, -2, and -3) (Figure 5b). The IC50 as determined by crystal violet staining for the 
normal or premalignant cells was in the range of 125 to 250 nM. Compromised cell viability 
was associated with substrate detachment of normal prostate epithelial cells and 
keratinocytes, as well as control PC3 cells (Supplementary Figure S5). Collectively, these 
results highlight a broad spectrum of inhibitory effects of RTA 408 on benign and malignant 
prostate cells and on normal prostate epithelial cells and keratinocytes in vitro. The effects 
on normal epithelial cells in vitro are in marked contrast to tissue protection of normal 
epithelial tissues in irradiated mice.
Inhibition of NF-κB activity by RTA 408 in vivo
The selective anti-tumor activity of RTA 408 on prostate cancer cell lines in vivo raises the 
question which molecular target(s) are responsible for this effect. In prostate cancer, 
deregulated NF-κB signaling is associated with disease progression, contributes to 
expression of both prostate specific antigen (PSA) (21) and androgen receptor (22), and is 
prevalent in castrate-resistant and metastatic tumors (23–26). Conversely, disrupting NF-κB 
signaling by forced expression of a phosphorylation-deficient IκB radiosensitizes PC3 
prostate cells in vitro (27). Other NF-κB inhibitors including curcumin (28), parthenolide 
(29), and SN52 (30) similarly inhibit prostate cancer growth and survival. Based on this 
prior work, we used NF-κB-NLuc- and control CMV-Fluc -reporter constructs to measure 
NF-κB activity in transfected PC3 tumors in vivo, before and after treatment with RTA 408 
and/or IR (Figure 6a,b). As expected, radiation induced NF-κB activity in tumor tissue 
(Figure 6, panel 4). In the post-treatment group the ratio of NF-κB-NLuc- to CMV-Fluc 
activity in RTA 408 treated mice (Figure 6, panel 6) was significantly lower compared to 
that observed in mice treated with vehicle alone (Figure 6, panel 2). In addition, the ratio of 
NF-κB-NLuc- to CMV-Fluc activity in mice treated with RTA 408 and IR combined 
(Figure 6, panel 8) was significantly lower compared to that observed in mice treated with 
IR alone (Figure 6, panel 4). Hence, at tumor growth-inhibitory concentrations RTA 408 
effectively inhibited transcription of an NF-κB-responsive reporter construct in PC3 cells in 
vivo.
These observations extend and confirm previous reports describing in vitro growth 
inhibition of human prostate cancer cells by CDDO variants. Specifically, Deeb et al. 
described proapoptotic effects of CDDO, CDDO-methyl(ME) and, CDDO-imidazole(IM) in 
cultured human LNCaP, PC3 and DU145 and murine TRAMPC-1 prostate cancer cells in 
vitro (31, 32). Furthermore, Gao et al. described CDDO-dependent chemoprevention of 
prostate cancer development in transgenic TRAMP mice in which the SV40 T antigen is 
expressed by prostate epithelial cells (33). Tumor growth inhibition by CDDO derivatives 
extends to other tumor types ranging from leukemias (34–37) to solid malignancies (38–42). 
A common denominator of these tumor types is deregulated NF-κB activity which is 
effectively inhibited by RTA 408 not only in vitro but also in vivo. It remains to be 
determined whether inhibition of survival pathways beyond NF-κB play a role in prostate 
cancer inhibition by RTA 408. For example, the Akt/mTOR pathway is also reportedly 
inhibited by CDDO-ME in prostate cancer cells (43).
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The mechanistic basis for the dual and opposite effects of RTA 408 on normal and a broad 
range of malignant tissues remains to be investigated further. Of particular relevance to 
cytoprotection, CDDO covalently attaches to KEAP1, disrupts KEAP1/Nrf2 interaction and 
triggers Nrf2-dependent transcription of a host of genes encoding antioxidant enzymes (16). 
Nrf-2 activation by the CDDO derivatives CDDO-ethylamide (EA) and CDDO-ME has 
been proposed to improve survival of irradiated mice (44). We observed that topical 
application of RTA 408 markedly reduced radiation dermatitis in mice associated with 
significant increases in Nrf2 target genes and significant decreases in NF-kB target genes 
(45). Interestingly, radiation protection of normal prostate epithelial cells contrasted by 
growth inhibition of prostate cancer cells in vivo has been very recently described for 
dimethylamineparthenolide (DMAPT) (46). DMAPT and its parent compound parthenolide 
alkylate reactive cysteines on multiple protein targets including KEAP1 and inhibit 
canonical NF-κB signaling by interacting with IκB and the NFκBp65 subunit (47–49). In 
contrast to RTA 408, parthenolide or DMAPT reportedly did not inhibit cultured normal or 
immortalized prostate cells to the same extent as their malignant counterparts and this 
difference has been attributed to differential effects of DMAPT on KEAP1-dependent 
oxidation status in normal and malignant cells (46). This difference between RTA 408 and 
DMAPT suggests that tissue protection by RTA 408 as seen in vivo is not primarily due to 
cell-autonomous effects but likely depends on environmental factors provided by the tissue 
context in vivo. A precedent for ‘contextual’ anti-tumor effects of CDDO-ME has been 
established previously (50). Specifically, CDDO-ME inhibited myeloid-derived suppressor 
cells in the tumor micorenvironment associated with improved immune responses. 
Regardless of the relative contribution of cell-intrinsic or ‘environmental’ anti-tumor 
mechanisms, the results obtained for DMAPT (46) and RTA 408 (this study) validate the 
concept of selective radiosensitization of tumor cell tissues by thiol reactive compounds (5).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Effects of signal transduction modifiers on survival of lethally irradiated mice. (a) Survival 
of mice pretreated (24 h) with the NF-κB inhibitors ethyl pyruvate (EP; 70 mg/kg) or RTA 
408 (17.5 mg/kg) and receiving 8 Gy single dose whole body radiation. Ethyl pyruvate was 
administered 15 min prior to IR and on days 1 – 3 post IR. RTA 408 was administered 1 d 
and 1 h pre-irradiation and on days 1 – 3 post IR. (b) Survival of mice treated with the 
GSK3 inhibitors Lithium chloride (LiCl; 40 mg/kg), SB415286 (1 mg/kg) and SB216673 (1 
mg/kg) and receiving 8 Gy single dose whole body radiation; treatment schedule for these 
compounds was 2 and 1 day prior to IR and daily on days 1 – 3 post IR. (c) Effects of select 
combinations of NF-κB and GSK3 inhibitors on survival of irradiated mice (8 Gy); 
treatment schedules for individual compounds as described under panel A. (d) Survival of 
irradiated mice (whole body, 9 Gy) treated with RTA 408 (17.5 mg/kg) at 24 and 1 h prior 
to IR and on days 1–2 post IR or with Amifostine (250 mg/kg) administered 15 min prior to 
IR. Experimental groups in each panel consisted of 5 animals each. P value summaries refer 
to pair-wise comparisons between IR and (IR + drug) treatment groups, generated by using 
the Log-rank (Mantel-Cox) test.
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Figure 2. 
RTA 408 reduces radiation-associated damage to the mucosal lining of the small intestine 
after single dose (9 Gy) radiation exposure. RTA 408 (17.5 mg/kg) was administered on 
days 1 – 3 post IR. (a) Assessment of gastrointestinal morphology was performed on tissue 
sections sampled days 2 and 7 after radiation exposure. Parallel sections were subjected to 
staining with Ki-67 reactive antibody to ascertain the proliferative state of the 
gastrointestinal stem cell compartment located in the crypt areas; scale bars = 100 µm. (b) 
Effects of RTA 408 on radiation-induced apoptosis incidence in the gastrointestinal mucosa. 
RTA 408 (17.5 mg/kg) was administered 24 h after IR (9 Gy) and small intestine tissues 
sampled at 48 h. Apoptosis incidence was determined by TUNEL staining and cell nuclei 
were counterstained with DAPI; scale bars = 100 µm. Results shown in panel D represent m
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±SD of at least 6 fields/per condition analyzed. The number of TUNEL positive cells was 
significantly (Student’s t-test (p<0.05)) reduced in irradiated animals receiving RTA 408 
when compared to vehicle-treated, irradiated animals.
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Figure 3. 
RTA 408 inhibits growth and survival of human prostate cancer xenotransplants. (a) Effects 
of RTA 408 on growth of DU145, PC3, LNCaP/C4-2B and CWR22Rv1 cells in vivo. RTA 
408 was administered (3× per week at 17.5 mg/kg) after tumors had reached volumes 
exceeding 25 – 30 mm3. Experimental groups consisted of 5 animals each. Results represent 
m±SD of these groups. P value summaries refer to tumor growth trajectories over time in 
RTA 408 and control groups. (b) Inhibition of PC3 xenograft growth and survival by 
combined radiation and RTA 408 treatment. Tumor-bearing mice were treated for 2 weeks 
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with either RTA 408 or RTA 408 and IR. IR (5 Gy) was administered twice on days 1 and 8 
and RTA 408 (17.5 mg/kg) was administered 1 d prior and for 3 days after each IR in the 
combination group. RTA 408 administration (3× weekly) was continued for further 4 weeks. 
Results represent m±SD of groups of 5 animals each. Tumor growth trajectories over time 
were compared between treatment and control groups, and among treatment groups. The 
insert shows representative images of tumors in situ at treatment start and 40 days after. 
Chemiluminescence was detected by IVIS bioimaging of PC3 cells constitutively expressing 
firefly luciferase.
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Figure 4. 
Effects of RTA 408 on apoptosis incidence and proliferation in PC3 prostate cancer 
xenografts treated with RTA 408. (a) Apoptosis incidence was determined by TUNEL and 
by immunohistochemical detection of cleaved PARP and cytokeratin 18 (M30) at different 
time intervals after treatment with RTA 408 commenced; scale bars = 100 µm. Quantitative 
analysis of the results obtained on day 15 of treatment was performed by averaging the 
number of positive cells in at least 6 different fields. Results are expressed as m±SD. 
Statistically significant (p<0.05) differences were determined by Student’s t-test. (b) RTA 
408-dependent inhibition of PC3 prostate cancer cell proliferation. Proliferating cells were 
detected by staining with Ki-67 antibody (red). Cell nuclei were counterstained with DAPI; 
scale bars = 100 µm. Tumors were harvested 15 days after treatment initiation.
Alexeev et al. Page 17
Mol Cancer Ther. Author manuscript; available in PMC 2015 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5. 
In vitro effects of RTA 408 on (a) prostate cancer cell and (b) normal cell growth and 
survival. Loss of viability was determined by assessing the numbers of adherent cells using 
crystal violet stain or measuring metabolic activity (WST assay). Experiments were 
performed in triplicate and repeated 2 times. Results shown are m±SD of triplicates of a 
representative experiment. Results are presented as percentages of vehicle control. Analysis 
by using one-way ANOVA with Tukey’s post-test correction (GraphPad Prism) revealed 
significant differences between RTA 408- and vehicle-treated groups (p<0.05 to p<0.001).
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Figure 6. 
In vivo imaging of NF-κB reporter activity in PC3 xenografts treated with either IR, or RTA 
408 or a combination of IR and RTA 408. (a) Representative images of mice showing 
expression of firefly luciferase (Fluc) under control of a CMV promoter and corresponding 
images showing activity of an NF-κB responsive promoter driving NanoLuc® (NLuc) 
expression are shown. Pre-treatment images were acquired 2 days prior to treatment with 
either RTA 408 or IR (panels 1, 3, 5, 7). Post-treatment images were acquired from the same 
mice either untreated or after short-term (1 h) treatment with RTA 408 (17.5 mg/kg) or after 
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IR (5 Gy) or RTA 408 (17.5 mg/ml; 2 d) and IR (5 Gy) as indicated (panels 2,4,6,8). Images 
in the post-treatment group were acquired 1 h after IR exposure. (b) Quantitative 
representation of NF-κB 24 activity expressed as the ratio of NanoLuc® to firefly luciferase 
(n = 2 per group). Labeling of the X-axis refers to treatment groups as shown in panel (a). 
Results shown are m±SD of duplicate mice in each group. This experiment was repeated 
with comparable results.
Alexeev et al. Page 20
Mol Cancer Ther. Author manuscript; available in PMC 2015 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
